Validation of L-type calcium channel blocker amlodipine as a novel ADHD treatment through cross-species analysis, drug-target Mendelian randomization, and clinical evidence from medical records
Update: 2025-06-04
Description
Attention deficit hyperactivity disorder, or ADHD, is a common condition that, for a lot of people, is difficult to treat. The drugs that exist have a number of adverse side effects, and about 25 percent of patients don’t respond to existing drugs. And so a team of researchers in Iceland, led by Karl Karlsson, professor of biomolecular engineering at Reykjavik University, undertook a number of different steps to narrow in on and then test what the team has determined to be a novel treatment for ADHD, using an existing drug, amlodipine.
Read the full study here: https://www.nature.com/articles/s41386-025-02062-x
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
